2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17037S
    Pirenzepine-d8 1189944-02-2 98%
    Pirenzepine-d8 is the deuterium labeled Pirenzepine dihydrochloride. Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.
    Pirenzepine-d8
  • HY-170381
    α-syn aggregation inhibitor-1 98%
    α-syn aggregation inhibitor-1 (Compound 2e) is an inhibitor for α-syn aggregation. α-syn aggregation inhibitor-1 inhibits the cell viability of SH-SY5Y.
    α-syn aggregation inhibitor-1
  • HY-170389
    BChE-IN-39 98%
    BChE-IN-39 (Compound 7c) is a selective inhibitor for butyrylcholinesterase (BChE) with an IC50 of 0.08 μM (IC50=3.98 μM for AChE). BChE-IN-39 downregulates the GSK-3β expression, inhibits the hyperphosphorylation of tau protein.
    BChE-IN-39
  • HY-170409
    BNN27 1195795-81-3 98%
    BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable.
    BNN27
  • HY-170417
    hAChE/hBuChE/GSK-3β-IN-1 98%
    hAChE/hBuChE/GSK-3β-IN-1 (Compound 6c) is a BBB-penetrable and multi-target anti-Alzheimer's disease compound. hAChE/hBuChE/GSK-3β-IN-1 is the inhibitors of hAChE (IC50: 28.88 nM), hBuChE (IC50: 131.90 nM) and GSK-3β (IC50: 51.42 nM). hAChE/hBuChE/GSK-3β-IN-1 is the tau and Aβ protein aggregation inhibitors.
    hAChE/hBuChE/GSK-3β-IN-1
  • HY-170437
    MOR modulator-1 2976336-81-7 98%
    MOR modulator-1 (compound 6) is a potent and selective μ opioid receptor (MOR) modulator. MOR modulator-1 exhibits improved opioid receptor selectivity, enhanced in vivo antagonistic effect, and overall fewer withdrawal symptoms compared to NAT (6α-configuration). MOR modulator-1 links with carboxamido linker μ, δ, γ with Kis of 0.25, 41.1, 1.30 nM, respectively[1]
    MOR modulator-1
  • HY-170444
    ADS1017 98%
    ADS1017 is the antagonist for histamine receptor and muscarinic receptor, that exhibits good affinities to hH3R, hH4R, hM2R and hM4R with pKi of 6.8, 5.5, 7.4 and 7.2. ADS1017 exhibits analgesic and anti-allodynic efficacy in mice Capsaicin (HY-10448)-or Oxaliplatin (HY-17371)-induced pain models.
    ADS1017
  • HY-170475
    5-MeO-MET 16977-53-0 98%
    5-MeO-MET (5-Methoxy-N-methyl-N-ethyltryptamine) is a 5-methoxytryptamines compound. 5-MeO-MET is the agonist of 5-HT1A and 5-HT2A. 5-MeO-MET can inhibit the movement of mice and has a sedative effect.
    5-MeO-MET
  • HY-170484
    KAI-11101 98%
    KAI-11101 is the inhibitor for dual leucine zipper kinase (DLK, MAP3K12) with a Ki of 0.7 nM. KAI-11101 inhibits Paclitaxel (HY-B0015)-induced cJun phosphorylation (IC50=95 nM) and thus inhibits the activation of MAPK pathway. KAI-11101 is blood brain barrier penetrable and can be further investigated for its neuroprotective property.
    KAI-11101
  • HY-170487
    MAO-B-IN-38 98%
    MAO-B-IN-38 (Compound 6b) is a reversible and competitive MAO-B inhibitor, with IC50 values of 0.03 and 21.46 µM for MAO-B and MAO-A, respectively. MAO-B-IN-38 can be used for the research of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases.
    MAO-B-IN-38
  • HY-170491
    GSK-3β inhibitor 23 98%
    GSK-3β inhibitor 23 (Compound 11726169) is the inhibitor for glycogen synthase kinase-3, that inhibits GSK-3β and GSK-3α with IC50 of 12.1 nM and 18.8 nM. GSK-3β inhibitor 23 exhibits antiviral activity against HIV 1. GSK-3β inhibitor 23 exhibits good metabolic stablility in mouse/human liver microsomes and plasma, but poor Caco-2 permeability (which predicts low oral bioavailability).
    GSK-3β inhibitor 23
  • HY-170498
    GABA-A Receptor Ligand-1 3076335-23-1 98%
    GABA-A Receptor Ligand-1 (Compound 4) is a ligand for GABA-A receptor with a pKi of 7.27. GABA-A Receptor Ligand-1 reduces mitochondrial dysfunction, promotes neurite outgrowth and neuronal regeneration. GABA-A Receptor Ligand-1 exhibits neuroprotective efficacy in rats ischemic stroke models.
    GABA-A Receptor Ligand-1
  • HY-170499
    VU6024578 98%
    VU6024578 (BI02982816) is a selective, orally active positive allosteric modulator (PAM) for metabotropic glutamate receptor (mGluR1), that activates human mGluR1 and rat mGluR1 with EC50 of 54 nM and 46 nM. VU6024578 exhibits antipsychotic activity in rats amphetamine-induced hyperactivity models and MK-801 (HY-15084B)-induced novel object recognition (NOR) models. VU6024578 is blood brain barrier penetrable.
    VU6024578
  • HY-170509
    Ferroptosis-IN-17 98%
    Ferroptosis-IN-17 (Compound 18) is a ferroptosis (Ferroptosis) inhibitor with an EC50 value of 0.57 μM. Ferroptosis-IN-17 reduces intracellular ferrous ion accumulation, lipid peroxidation, and effectively restores the levels of glutathione (GSH) and glutathione peroxidase 4 (GPX4). Ferroptosis-IN-17 shows good solubility and significant metabolic stability in rat plasma. Ferroptosis-IN-17 is promising for research in tumor suppression, neurodegenerative diseases, and cardiovascular diseases.
    Ferroptosis-IN-17
  • HY-170531
    SR 142948-C3-NHMe 1613265-52-3 98%
    SR 142948-C3-NHMe is the methylated SR 142948 (HY-107664).
    SR 142948-C3-NHMe
  • HY-170532
    NLRP3-IN-63 3064696-02-9 98%
    NLRP3-IN-63 (Compound 7) is an inhibitor for NLRP3, that inhibits the NLRP3 activation with an EC50 of 13 nM.
    NLRP3-IN-63
  • HY-170553
    ZPD-2 98%
    ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease.
    ZPD-2
  • HY-170560
    AChE/hCA I-IN-1 155140-19-5 98%
    AChE/hCA I-IN-1 (Compound L3) is the inhibitor for acetylcholinesterase (AChE) and carbonic anhydrase (CA), that inhibits AChE, hCA I and hCA II with IC50 of 302, 265 and 283 nM, respectively.
    AChE/hCA I-IN-1
  • HY-170561
    AChE/BuChE-IN-6 98%
    AChE/BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and BuChE, with IC50 values of 1.24 and 1.85 μg/mL, respectively. AChE/BuChE-IN-6 also exhibits strong DPPH free radical scavenging activity (IC50 = 3.15 μg/mL). In vivo toxicity studies indicate that AChE/BuChE-IN-6 is safe, showing no significant differences in blood and biochemical markers compared to the control group after long-term administration, and no abnormalities were observed in liver and kidney tissues. AChE/BuChE-IN-6 holds promise for research into Alzheimer's disease.
    AChE/BuChE-IN-6
  • HY-170562
    STEP-IN-1 98%
    STEP-IN-1 (Compound 14b) is a potent and selective STEP inhibitor with an IC50 of 5.27 μM. STEP-IN-1 has a neuroprotective effect, which can protect nerve cells from glutamate-induced toxicity, reduce cellular ROS accumulation, and inhibit apoptosis. STEP-IN-1 can be used in the study of neurodegenerative diseases.
    STEP-IN-1
Cat. No. Product Name / Synonyms Application Reactivity